The acquisition expands Lilly’s pain pipeline with a slate of drugs targeting ion channel proteins like NaV1.7 and NaV1.8.

Eli Lilly and Purdue University, US, have announced the widening of their existing partnership with a planned investment of up to $250m.

The U.S. imports more pharmaceutical products from Ireland than from any other country -- nearly $50 billion last year. It won't be surprising if the Trump administration especially targets those ...

INDIANAPOLIS and WEST LAFAYETTE, Ind. - Eli Lilly and Company (NYSE: LLY), a pharmaceutical giant with annual revenue exceeding $49 billion and an impressive 81.7% gross profit margin, and Purdue ...

INDIANAPOLIS and WEST LAFAYETTE, May 9, 2025 — Eli Lilly and Company (NYSE: LLY) and Purdue University announced Friday (May 9) a significant expansion of their long-standing alliance ... at every ...

In its second R&D alliance this week, Eli Lilly has formed a partnership with ... Earlier this week, the pharma group announced a $1 billion alliance with Swiss start-up Haya Therapeutics to ...

Eli Lilly and Co. CEO David Ricks ... $250 million over the next eight years to foster pharmaceutical innovation. The initiative, called Lilly-Purdue 360, is focused on efforts including ...

Sidekick is also working with a number of other pharma companies on companion ... and other chronic conditions. The new Lilly alliance is one of three that Sidekick expects to announce in the ...

The investment over the next eight years could be the largest ever industry-academic agreement of its kind in the U.S., the ...

Eli Lilly and Co. and Purdue University announced today a significant expansion of their long-standing alliance ... innovation at every stage of the pharmaceutical pipeline.